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In this era of evidence-based medicine, before any new 10.5 mL/min in order to prevent uremic complications.
treatment can be approved, clinical trials are required to For patients with diabetes, there is consensus that RRT
establish treatment efficacy in terms of relevant clinical should be initiated even earlier [1]. But in reality, dialysis
end points. For most large trials in kidney disease, the is delayed, with 57% of all patients in the United States
hard end point employed is “renal death” or end-stage starting dialysis with a residual GFR less than 7 mL/min
renal disease (ESRD). Both terms are used interchange- [2]. This implies that the majority of patients are uremic
ably to denote the extent of renal failure that, if untreated for a considerable time before starting RRT. While late
by dialysis or transplantation, would result in the death initiation of dialysis may be indicative of late presenta-
of the patient from complications of uremia. As dialysis tion or tardy referral, at least some of the delay is due
has become an acceptable and commonplace treatment, to impaired access to RRT outside tertiary care centers.
ESRD is rarely fatal. However, there remain many situa- Women and certain non-Caucasian racial groups are
tions where safe dialysis is impractical or inappropriate. more likely to have delayed initiation of dialysis [3].
For example, many of the patients with pre-ESRD in the Furthermore, American patients who do not have insur-
Western world may be unsuitable for renal replacement ance have significantly greater odds of late initiation of
therapy (RRT) because of age, frailty, or a co-morbid dialysis compared to patients with private insurance [3].
illness with poor prognostic outcome. In addition, the Therefore, in most regions of the world, and especially
majority of the hundreds of thousands of patients with outside the setting of the clinical trial, the frequency of
renal failure reside in developing countries without the uremic symptoms, malnutrition, and the possibility of
resources or infrastructure to provide for universal RRT. life-threatening complications are all increased in pa-
In these circumstances, dialysis delayed is death prevented. tients prior to starting dialysis.
In addition, within the intensive review of a clinical Recent trials in the prevention of ESRD deserve to
trial, initiation of RRT is almost always timely and opti- be considered in light of these “real world” conditions.
mized in order to avoid the consequences of terminal Many studies have been criticized on the grounds that
uremia and reduce morbidity and mortality. But in the their interventions appear to lack applicability outside
“real world,” particularly the disadvantaged regions the highly specialized setting of the clinical trial. Results
where health resources are limited, conditions are sel- achieved in such studies can seldom be reproduced in
dom optimal for ESRD patients. Dialysis tends to be routine practice. But the opposite argument may also be
considered, if at all, only after conservative therapy be- made. It may be observed that as a result of being con-
comes insufficient for controlling the clinical or biologic fined to the highly specialized setting, a trial may poten-
dysfunctions of the uremic state. The National Kidney tially underestimate the extent of benefits that may be
Foundation-Dialysis Outcome Quality Initiative (NKF achieved in everyday practice. A case in point is the
DOQITM) guidelines recommend that patients begin dial- recent RENAAL trial [4] that showed a 28.8% risk re-
ysis when the glomerular filtration rate (GFR) falls below duction for ESRD with therapy with the angiotensin II
antagonist losartan (P  0.002). However, the all-cause
mortality (including both pre- and post-ESRD deaths)Key words: angiotensin II antagonist, death, dialysis, end-stage renal
disease. was not significantly different from placebo (2%) pos-
sibly as this study was performed in centers where
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where RRT is not readily available and recognition of In addition, although including patients with lesser
degrees of renal impairment [e.g., serum creatinine 1.3renal disease occurs late or not at all, ERSD prevented
could equate to reduced mortality. Using the composite mg/dL (115 mol/L)] may have been valuable to demon-
strate that losartan works equally well in early and ad-outcome “death or ESRD” to identify both actual predi-
alysis mortality and renal death, losartan resulted in a vanced diabetic nephropathy, patients with only mild
renal impairment at the outset may not have been ex-20% reduction in risk. In the absence of RRT, this di-
rectly translates into fewer deaths. In America, over 20% posed to a uremic milieu during the average 31⁄2 years
of the study course. Both the timely initiation of dialysisof all patients with pre-ESRD are said to be unsuitable
for RRT [5]. In addition, the RENAAL study excluded and inclusion of patients with early diabetic renal disease
may to some extent explain why predialysis mortalitypatients with heart failure and significant vascular disease.
Again, had the RENAAL study included these kinds of could be underrepresented in the RENAAL study.
If prevention of ESRD represents the prevention ofpatients, the all-cause mortality may have been different.
Approximately two thirds of all deaths (214/313, 64%) renal death, efficacy analysis should therefore consider
pre-ESRD outcomes and establish death or dialysis asin the RENAAL study occurred before starting dialysis,
the majority due to premature cardiovascular disease. The the primary end point. In effect, death and dialysis are
competing events in the study population. However, onereasons for this may be multifactorial, including hyperten-
sion, oxidative stress, inflammation, malnutrition, and dys- third of all deaths (99/313, 32%) in the RENAAL study
occurred after starting dialysis. Of all patients reachinglipidemia [6]. The uremic environment per se may also
be atherogenic. The uremic syndrome is characterized by ESRD, 22.6% (77/341) died within the first year of RRT.
This mortality rate is higher than the first annual mortal-deterioration in biochemical and physiologic functions in
parallel with the progression of renal disease. As with ity of around 15% seen in most dialysis centers [9, 10],
presumably reflecting the impact of diabetic co-morbid-some large studies in the past [7], RENAAL also demon-
strated that, independent to other baseline covariates, ity on dialysis outcomes. While it is possible that at least
some of post-ESRD mortality in the RENAAL studyserum creatinine was a significant risk factor for all-cause
mortality (76% risk increase per 1 mg/dL increase in was not modified by dialysis, the timely initiation of RRT
in study patients would also have been exposed earlierserum creatinine, P 0.0001) and cardiovascular mortal-
ity (83% risk increase per 1 mg/dL increase in serum to the life-threatening complications associated with dial-
ysis (i.e., sepsis, hypotension, and repeated invasive in-creatinine, P  0.0001) in patients with type 2 diabetes
and nephropathy. In effect, the more advanced the renal terventions). Furthermore, once a patient starts dialysis,
many different factors may contribute to mortality, anddisease, the greater the perturbation of uremic indices
and the greater the mortality risk. dialysis itself may introduce other risk factors for mortal-
ity. Consequently, the inclusion of post-ESRD deaths inIf slowing progression to ESRD actually reduces mor-
tality, it is possible that this benefit may only be detected the total mortality figure may bias away from potentially
more clinically relevant predialysis events. Future trialsin patients where the pre-ESRD milieu was postponed
by therapy. However, in the study setting and in accor- evaluating the renoprotective effects of an intervention
could do better to analyze death or ESRD together asdance with guidelines (compared to the “real world”),
few patients are allowed to become and stay uremic. In competing events in time to first-event analysis.
In addition to reducing total ESRD events, the rateparticular, the timely initiation of RRT attenuates the
complications of chronic renal failure such as malnutri- of decline in renal function was significantly slowed in
patients treated with losartan (4.4 vs. 5.2, P  0.01)tion and cardiovascular disease and consequently results
in reduced morbidity, mortality, and cost [3] (possibly as reducing reduce the number of days with ESRD by 213
days per patient (abstract; Keane et al, J Am Soc Nephrola result of initiating dialysis earlier in the disease process
[8]). Patients reaching ESRD in the RENAAL study 13:264A, 2002). In the “real world,” where dialysis de-
layed equals death prevented, this means a longer lifestarted dialysis earlier than is current practice in the “real
world” outside the trial setting. The estimated mean span. Even in centers that are able to offer universal
RRT, the capacity to delay the progression of renal dis-GFR for patients starting RRT (in whom serum creati-
nine was available 3 months prior to ESRD) was 10.8 ease may also be compatible with a more conservative
approach to care, allowing for the planning and timelymL/min/1.73 m2 (median  10.3). In the “real world,”
with dialysis initiated on average at 7 mL/min/1.73 m2 initiation of RRT and reducing the need for and the
consequences of emergent dialysis. In nondiabetic chronicthe duration of “pre-ESRD” is much longer, increasing
the potential for mortality during this time. In quantita- nephropathies, the capacity to delayed progression to
ESRD by angiotensin-converting enzyme (ACE) inhibi-tive terms (using the pooled rate of disease progression
of 4 to 5 mL/min/1.73 m2/year) RRT in the RENAAL tor therapy results not only in the prolongation of pa-
tients survival, but also in an increased proportion ofstudy provided nearly 8 to 12 months less of uremia than
is currently standard in most places in the world. time spent on conservative therapy [11]. Moreover, many
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